Wantai BioPharm - Public Comps and Valuation Multiples

Wantai BioPharm Overview

About Wantai BioPharm

Beijing Wantai Biological Pharmacy Enterprise Co Ltd is engaged in research, development, production, and sales of in vitro diagnostic reagents, instruments, and vaccines. The company has two segments: Diagnostic and Vaccine. The Diagnostic segment develops and sells in vitro diagnostic reagents such as ELISA, colloidal gold, biochemical, and chemiluminescent kits, along with instruments including chemiluminescent analyzers, fluorescent analyzers, and nucleic acid purification systems. The Vaccine segment focuses on products like the hepatitis E vaccine, the bivalent HPV vaccine, and the nasal spray COVID-19 vaccine. It generates the majority of its revenue from the Diagnostic segment.

Founded

1991

HQ

Employees

3.8K+

Website

ystwt.com

Sectors

Vaccines & Immunotherapies
Pharma Diagnostics & Analytics
BioTech

Financials

Last FY Revenue $315M

Last FY EBITDA $52.8M

EV

$9.3B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Wantai BioPharm Financials

In the same period, Wantai BioPharm achieved $1.9M in LTM net income.

See Wantai BioPharm valuation multiples based on analyst estimates

Wantai BioPharm P&L

In the most recent fiscal year, Wantai BioPharm reported revenue of $315M and EBITDA of $52.8M.

Wantai BioPharm expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Wantai BioPharm valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	n/a	XXX	$315M	XXX	XXX	XXX
Gross Profit	n/a	XXX	$208M	XXX	XXX	XXX
Gross Margin	n/a	XXX	66%	XXX	XXX	XXX
EBITDA	n/a	XXX	$52.8M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	17%	XXX	XXX	XXX
EBIT	n/a	XXX	$0.3M	XXX	XXX	XXX
EBIT Margin	n/a	XXX	0%	XXX	XXX	XXX
Net Profit	$1.9M	XXX	$14.9M	XXX	XXX	XXX
Net Margin	n/a	XXX	5%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Wantai BioPharm including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Wantai BioPharm achieved $315M in revenue and $52.8M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	n/a	Analyst estimates available to subscribers	$315M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	$208M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	66.2% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	n/a	Analyst estimates available to subscribers	$52.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	n/a	Analyst estimates available to subscribers	16.8% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	n/a	Analyst estimates available to subscribers	$0.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	n/a	Analyst estimates available to subscribers	0.1% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$1.9M	Analyst estimates available to subscribers	$14.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	n/a	Analyst estimates available to subscribers	4.7% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Wantai BioPharm

This financial data table provides comprehensive performance metrics for Wantai BioPharm, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Wantai BioPharm reported $315M in total revenue.
Fiscal year EBITDA was $52.8M.
The company maintained a gross profit margin of 66.2% in the most recent fiscal year.
EBITDA margin for the fiscal year was 16.8%.
Net profit margin reached 4.7% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Wantai BioPharm. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Wantai BioPharm Stock Performance

Wantai BioPharm has current market cap of CNY 69.7B (or $9.8B), and EV of CNY 66.2B (or $9.3B).

Market Cap Evolution

Wantai BioPharm Stock Data

As of October 17, 2025, Wantai BioPharm's stock price is CNY 55 (or $8).

See Wantai BioPharm trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$9.3B	$9.8B	XXX	XXX	XXX	XXX	$0.00

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Wantai BioPharm Valuation Multiples

Wantai BioPharm's trades at 29.5x EV/Revenue multiple, and 175.8x EV/EBITDA.

See valuation multiples for Wantai BioPharm and 15K+ public comps

Wantai BioPharm Financial Valuation Multiples

As of October 17, 2025, Wantai BioPharm has market cap of $9.8B and EV of $9.3B.

Equity research analysts estimate Wantai BioPharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Wantai BioPharm has a P/E ratio of 5136.2x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$9.8B	XXX	$9.8B	XXX	XXX	XXX
EV (current)	$9.3B	XXX	$9.3B	XXX	XXX	XXX
EV/Revenue	n/a	XXX	29.5x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	175.8x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	28762.6x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	5136.2x	XXX	655.9x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-124.3x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Wantai BioPharm Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Wantai BioPharm Margins & Growth Rates

Wantai BioPharm's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Wantai BioPharm's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Wantai BioPharm's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Wantai BioPharm and other 15K+ public comps

Wantai BioPharm Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	7%	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	17%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	-52%	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	17%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	39%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	66%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial